Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xiyanping Injection for COVID-19 Pneumonia
NCT04295551Unknown
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Start
- Mar 2020
- Primary completion
- Jul 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
01
Overview
Randomised, open-label trial of andrographolide sulfonate in coronavirus disease 2019 (COVID-19), sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd. Primary endpoint: Clinical recovery time at Day 28. Status: unknown.
02
Drugs
andrographolide sulfonate
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04295551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04295551.